Clinical Trials
50 trialsDonor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Massachusetts General Hospital
ALPHA
Allogene Therapeutics
SELECT-CAR-NK
Essen Biotech
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
ZUMA-5
Gilead Sciences
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Sana Biotechnology
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
TRANSCEND FL
Celgene
ZUMA-22
Gilead Sciences
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
University of Maryland, Baltimore
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech, Inc.
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
GLEAN-1
Adicet Therapeutics
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
PACIFICO
University of Liverpool
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Synthekine
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Fred Hutchinson Cancer Center
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
University Hospital Heidelberg
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
BMT CTN 0202
Medical College of Wisconsin
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
THALLO
Baylor College of Medicine
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
Lymphoma Study Association
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Pfizer
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
MatchCART
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
CTI BioPharma
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Duke University
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Millennium Pharmaceuticals, Inc.
Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
The Korean Society of Pediatric Hematology Oncology
Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab
Gruppo Italiano Studio Linfomi
Randomized Study for Patients With Follicular Lymphoma Needing Treatment
Lymphoma Study Association